The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]
  • Gene obtained from curated document aligns with the Allele Registry but not with ClinVar data
  • No CSPEC computer assertion could be determined for this classification!


Variant: NM_001754.5(RUNX1):c.-60+38dup

CA637749766

1268886 (ClinVar)

Gene: RUNX1
Condition: hereditary thrombocytopenia and hematologic cancer predisposition syndrome
Inheritance Mode: Autosomal dominant inheritance
UUID: e045b5a6-1aa6-4f0d-b25e-9f817a8381dc
Approved on: 2024-06-24
Published on: 2024-06-24

HGVS expressions

NM_001754.5:c.-60+38dup
NM_001754.5(RUNX1):c.-60+38dup
NC_000021.9:g.35049130dup
CM000683.2:g.35049130dup
NC_000021.8:g.36421427dup
CM000683.1:g.36421427dup
NC_000021.7:g.35343297dup
NG_011402.2:g.940596dup
ENST00000675419.1:c.-60+52dup
ENST00000300305.7:c.-217dup
ENST00000416754.1:c.-95dup
ENST00000437180.5:c.-60+52dup
ENST00000455571.5:c.-60+52dup
ENST00000475045.6:c.-59-158dup
ENST00000482318.5:c.-60+52dup
NM_001754.4:c.-60+52dup
NM_001754.5:c.-60+52dup
More

Benign

Met criteria codes 4
BP7 BP4 BP2 BA1
Not Met criteria codes 21
BS4 BS3 BS1 BS2 BP1 BP3 PVS1 PS4 PS2 PS1 PS3 PP1 PP3 PP2 PP4 PM6 PM2 PM5 PM1 PM4 PM3

Evidence Links 0

Expert Panel

Criteria Specification Information

Criteria Specification: ClinGen Myeloid Malignancy Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines Version 2

PDF
Criteria Specification Approval History
Criteria Specifications for this VCEP
Evidence submitted by expert panel
Myeloid Malignancy VCEP
The NM_001754.5(RUNX1):c.-60+52dup variant is a deep intronic variant in a homopolymer region that is not predicted by SpliceAI to impact splicing (BP4). The variant highest minor allele frequency (MAF) is 0.05560 (5.0%, 396/7122 alleles) in the African/African American subpopulation of the gnomAD2.1.1 ( ≥ 0.0015 (0.15%) (BP1)). Additionally, this variant is detected in a homozygous state in 10 individuals in a population database (gnomADv2.1.1) (BP2). This deep intronic variant is not well conserved with a phyloP100way score of 0.9 (BP7 ≤2.0). It has not been reported in individuals meeting at least one of the RUNX1 phenotypic criteria. In summary, the clinical significance of this variant is Benign. ACMG/AMP criteria applied, as specified by the Myeloid Malignancy Variant Curation Expert Panel for RUNX1: BP1, BP2, BP4, BP7
Met criteria codes
BP7
This deep intronc variant is not well conserved with a phyloP100way score of 0.9 (≤2.0)
BP4
SpliceAI score of 0.03 (≤ 0.20)
BP2
This variant is detected in a homozygous state in 10 individuals in a population database (gnomADv2.1.1)
BA1
MAF of 0.05560 (5.0%, 396/7122 alleles) in the African/African American subpopulation of the gnomAD2.1.1 cohort is ≥ 0.0015 (0.15%)
Not Met criteria codes
BS4
No case study found
BS3
No studies found
BS1
BA1 Met
BS2
This rule is not applicable for MM-VCEP
BP1
This rule is not applicable for MM-VCEP
BP3
This rule is not applicable for MM-VCEP
PVS1
Not predicted to be a null variant
PS4
No case study found
PS2
No case study found
PS1
No amino acid change predicted
PS3
No studies found
PP1
No case study found
PP3
Not a missense variant
PP2
This rule is not applicable for MM-VCEP
PP4
This rule is not applicable for MM-VCEP
PM6
No case study found
PM2
BA1 Met
PM5
Not a missense variant
PM1
Not in a hotspot or well established functional domain
PM4
No change in protein length predicted
PM3
This rule is not applicable for MM-VCEP
Curation History
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
¤ Powered by BCM's Genboree.